Elutia Inc. (ELUT)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Elutia Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 8 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 0.87 $ — 19% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
0/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -15.2%
- Exp. sales growth 3Y > 5% 3.2%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 3.2%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% –
- ROCE > 15% –
- Expected return > 10% –
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 474.7% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 2
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.60 | -0.60 – -0.60 | 12 | – | 1 |
| 12/31/2027 | -0.52 | -0.52 – -0.52 | 13 | – | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.15 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.20 | – | 6 | -6.90 | -165.70 | -12 | -12 |
| 2025: Q1 | -0.09 | – | 6 | -9.90 | -65.20 | -9 | -9 |
| 2025: Q2 | -0.22 | – | 6 | -0.40 | -153.40 | -8 | -8 |
| 2025: Q3 | -0.09 | -400.80 | 3 | -43.90 | -116.40 | -3 | -4 |
| 2025: Q4 | 1.60 | – | 3 | -40.20 | 2,164.20 | -25 | -26 |
| 2026: Q1 | -0.17 | – | 3 | -48.40 | -239.90 | -8 | -8 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2018 | 39 | -8 | -12 | -1.08 | -5 | -43 | 48 |
| 2019 | 43 | -8 | -12 | -1.12 | -7 | -55 | 45 |
| 2020 | 43 | -14 | -22 | -2.13 | -14 | 21 | 83 |
| 2021 | 47 | -23 | -25 | -2.38 | -15 | 14 | 67 |
| 2022 | 24 | -35 | -33 | -2.38 | -21 | -5 | 69 |
| 2023 | 25 | -31 | -38 | -2.07 | -22 | -39 | 43 |
| 2024 | 24 | -36 | -54 | -1.86 | -23 | -46 | 36 |
| 2025 | 12 | -18 | 53 | 1.16 | -45 | 28 | 62 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Elutia Inc., ein Unternehmen in der Vermarktungsphase, konzentriert sich auf die Entwicklung wirkstofffreisetzender Biomatrix-Produkte für den Einsatz in der chirurgischen Rekonstruktion und verwandten Anwendungen.
| Employees | 25 |
|---|---|
| Headquarters | Gaithersburg, MD |
| Address | 20 Firstfield Road, 20878 Gaithersburg, United States |
| Phone | 240 247 1170 |
| Website | elutia.com |
| IPO Date | 7. Sep 2023 |
| ISIN | US05479K1060 |
Management
| Name | Title | Birth Year |
|---|---|---|
| C. Randal Mills Ph.D. | Co-Founder, President, CEO & Director | 1972 |
| Matthew B. Ferguson | Chief Financial Officer | 1968 |
| Michelle LeRoux Williams Ph.D. | Chief Scientific Officer | 1975 |
| Tamara Grossett | Head of People | – |
| Sonali Fonseca Ph.D. | VP & Head of Emerging Businesses | – |
| Dwayne Montgomery | Head of Cardiovascular | 1968 |
| Peter J. Ligotti | Chief Commercial Officer | – |
| Jeffry D. Hamet | Senior VP of Finance, Treasurer & Secretary | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.